The Minimal Residual Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Minimal Residual Disease pipeline products will significantly revolutionize the Minimal Residual Disease market dynamics.
Minimal Residual Disease Overview
Minimal Residual Disease (MRD) is a small number of cancer cells left in the body after treatment. These cells have the potential to come back and cause relapse. In leukemia, for example, physicians look for a response after chemotherapy treatment by looking under the microscope for cancer cells present in a bone marrow biopsy.
An MRD positive test result means that the disease was still detected after the Minimal Residual Disease treatment. An MRD negative result means that no disease was detected after the Minimal Residual Disease treatment. For patients who are MRD positive, the number of remaining cancer cells may be so small that they cannot be detected through traditional tests, such as viewing cells under a microscope.
Some of the key facts of the Minimal Residual Disease Market Report
- The Minimal Residual Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In the year 2021, the total minimal residual disease testing cases in the 7MM were found to be 1,219,739 cases
- The most number of minimal residual disease testing cases were found in the United States followed by Germany
- The total number of minimal residual disease testing for Haematopoietic Stem CellTtransplantation HSCT related transplant in EU-5 were found to be 134,386 in the year 2021
- Key Minimal Residual Disease Companies: ICON plc, Amgen, Foresight Diagnostics, Adaptive Biotechnologies, Janssen Research & Development, LLC, Targeted Locus Amplification (TLA) technology, and others
- Key Minimal Residual Disease Therapies: ClonoSEQ, Blinatumomab, PhasED-Seq, Cergentis B.V., Daratumumab, MRDx BCR-ABL Test, and others
Get a Free sample for the Minimal Residual Disease Market Report
Key benefits of the Minimal Residual Disease Market report:
- Minimal Residual Disease market report covers a descriptive overview and comprehensive insight of the Minimal Residual Disease Epidemiology and Minimal Residual Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Minimal Residual Disease market report provides insights on the current and emerging therapies.
- Minimal Residual Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Minimal Residual Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Minimal Residual Disease market.
Discover more about therapies set to grab major Minimal Residual Disease market share @ Minimal Residual Disease market forecast
Minimal Residual Disease Epidemiology Segmentation:
The Minimal Residual Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Minimal Residual Disease
- Prevalent Cases of Minimal Residual Disease by severity
- Gender-specific Prevalence of Minimal Residual Disease
- Diagnosed Cases of Episodic and Chronic Minimal Residual Disease
Minimal Residual Disease Market
The dynamics of the Minimal Residual Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as PhasED-Seq, Cergentis B.V., and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Minimal Residual Disease epidemiology trends @ Minimal Residual Disease Epidemiological Insights
Minimal Residual Disease Market Strengths
- Several organizations and companies like the European Scientific foundation for Laboratory Hemato Oncology (ESLHO), Leukemia and Lymphoma Society (LLS) and
- European LeukemiaNet (ELN), among many more, are raising awareness about the disease, which can lead to the increased patient pool
- The recent advances in high-throughput technologies in molecular genetics may now provide a novel approach to detect MRD like next-generation sequencing (NGS)
Minimal Residual Disease Therapies
- ClonoSEQ: ICON plc
- Blinatumomab: Amgen
- PhasED-Seq: Foresight Diagnostics
- Cergentis B.V.: Adaptive Biotechnologies
- Daratumumab: Janssen Research & Development, LLC
- MRDx BCR-ABL Test: Targeted Locus Amplification (TLA) technology
Minimal Residual Disease Key Companies
- ICON plc
- Amgen
- Foresight Diagnostics
- Adaptive Biotechnologies
- Janssen Research & Development, LLC
- Targeted Locus Amplification (TLA) technology
Minimal Residual Disease Market Opportunities
- Increased use of MRD testing can create new opportunities by identifying the patients who could benefit from consolidative HDT-ASCT and/or prolonged therapy
- The development of more accurate diagnostic methods with high sensitivity can detect even the smallest amount of Minimal Residual Disease cells
Scope of the Minimal Residual Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Minimal Residual Disease Companies: ICON plc, Amgen, Foresight Diagnostics, Adaptive Biotechnologies, Janssen Research & Development, LLC, Targeted Locus Amplification (TLA) technology, and others
- Key Minimal Residual Disease Therapies: ClonoSEQ, Blinatumomab, PhasED-Seq, Cergentis B.V., Daratumumab, MRDx BCR-ABL Test, and others
- Therapeutic Assessment: Minimal Residual Disease current marketed and Minimal Residual Disease emerging therapies
- Minimal Residual Disease Market Dynamics: Minimal Residual Disease market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Minimal Residual Disease Market Access and Reimbursement
Table of Contents
1. Minimal Residual Disease Market Report Introduction
2. Executive Summary for Minimal Residual Disease
3. SWOT analysis of Minimal Residual Disease
4. Minimal Residual Disease Patient Share (%) Overview at a Glance
5. Minimal Residual Disease Market Overview at a Glance
6. Minimal Residual Disease Disease Background and Overview
7. Minimal Residual Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Minimal Residual Disease
9. Minimal Residual Disease Current Treatment and Medical Practices
10. Minimal Residual Disease Unmet Needs
11. Minimal Residual Disease Emerging Therapies
12. Minimal Residual Disease Market Outlook
13. Country-Wise Minimal Residual Disease Market Analysis (2019–2032)
14. Minimal Residual Disease Market Access and Reimbursement of Therapies
15. Minimal Residual Disease Market drivers
16. Minimal Residual Disease Market barriers
17. Minimal Residual Disease Appendix
18. Minimal Residual Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Minimal Residual Disease treatment, visit @ Minimal Residual Disease Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/